Shirley Michelle Shiller, DO

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular diagnostics in gastrointestinal (GI) cancers.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing in gastrointestinal malignancies.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses a patient’s hereditary predisposition to cancer.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular testing in gastrointestinal cancers.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses the difficulties that are preventing a more streamlined approached in testing for biomarkers.

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute’s Advisory Committee, Baylor University Medical Center, discusses the emerging technology of liquid biopsies and the clinical success associated with them.